Amelioration of Sepsis by Macrophage Activation
Amelioration of Sepsis by Macrophage Activation
批准号:
7679385
负责人:
David L. Williams
金额:
$28.71万
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-04-01 至 2011-08-31
关键词:
1-Phosphatidylinositol 4-KinaseAbbreviationsAdult Respiratory Distress SyndromeApoptosisBasic ScienceBindingCarbohydratesCell ProliferationComplexCritical IllnessDataDevelopmentDiseaseEnzymesEventFamilyFeedbackGlucansGlycogenGoalsGrantHomeostasisHomologous GeneITAMITGAM geneImmune responseImmunocompetentInflammationInflammatoryInflammatory ResponseInjuryKnowledgeLigandsLigationLinkMacrophage ActivationMacrophage-1 AntigenMembraneMolecularMorbidity - disease rateMusMyelogenousNuclearOutcomePDPK1 genePTEN genePathway interactionsPatientsPattern recognition receptorPhenotypePhosphatidylinositol 4,5-DiphosphatePhosphatidylinositolsPhosphotransferasesPhysiologicalPlayProto-Oncogene Proteins c-aktPuncture procedureReceptor SignalingReportingResearchResearch PersonnelResistanceRoleSepsisSepsis SyndromeSeptic ShockSignal PathwaySignal TransductionSplenocyteStreamSurface Plasmon ResonanceTRAF6 geneToll-Like Receptor 2Toll-like receptorsTyrosinecytokinedectin 1effective therapyimprovedinositol-1,4,5-trisphosphate 5-phosphatasenovel therapeutic interventionpreventreceptorresponsescavenger receptorseptictensintraffickingtreatment strategy
中文摘要
描述(由申请方提供):危重患者经常出现复杂的疾病谱,可能包括成人呼吸窘迫综合征(ARDS)、全身炎症反应综合征(SIRS)、脓毒症综合征和/或脓毒性休克。目前,我们不了解参与脓毒症损伤的启动和传播的细胞和分子机制;我们也不了解试图限制炎症、维持稳态和促进脓毒症患者存活的先天生理机制。磷脂酰肌醇3-激酶/Akt(PI 3 K/Akt)是一个保守的信号转导酶家族,参与调节细胞增殖和存活。在上一个研究期间,我们发现PI 3 K家族的信号转导酶通过限制对微生物败血症的炎症反应而发挥重要的生理作用。具体而言,内源性PI 3 K抑制脓毒症宿主中的促炎性细胞因子释放和细胞凋亡。它还能促进暴发性脓毒症患者的存活。更重要的是,我们发现由膜相关模式识别受体结合的碳水化合物配体刺激PI 3 K/Akt通路,导致暴发性脓毒症的发病率降低和生存结局增加。这些数据表明,刺激PI 3 K通路可能是预防和/或治疗脓毒症/脓毒性休克的有效方法。在目前的建议中,我们将扩展这些研究,以检查葡聚糖配体刺激PI 3 K/Akt信号传导的细胞和分子机制。我们将重点了解激活PI 3 K的配体-受体相互作用,刺激PI 3 K/Akt/GSK 3的受体后信号转导事件,以及最终导致PI 3 K调节和诱导脓毒症损伤中保护性表型的细胞变化。这项研究的结果不仅将增加我们对炎症/脓毒性疾病的先天反应的基础科学知识,而且还可能导致为几种重要疾病状态开发新的治疗策略。
英文摘要
DESCRIPTION (provided by applicant): The critically ill patient frequently develops a complex disease spectrum that may include adult respiratory distress syndrome (ARDS), systemic inflammatory response syndrome (SIRS), sepsis syndrome and/or septic shock. At present, we do not understand the cellular and molecular mechanisms that are involved in the initiation and propagation of septic injury; nor do we understand the innate physiologic mechanisms that attempt to limit inflammation maintain homeostasis and promote survival in the septic patient. The phosphoinsitide 3-kinases/Akt (PI3K/Akt) is a conserved family of signal transduction enzymes which are involved in regulating cellular proliferation and survival. During the last grant period, we discovered that the PI3K family of signal transduction enzymes plays an important physiologic role by limiting the inflammatory response to plymicrobial sepsis. Specifically, endogenous PI3K suppresses pro-inflammatory cytokine release and apoptosis in the septic host. It also promotes survival in fulminating sepsis. Of greater significance, we discovered that a carbohydrate ligand that is bound by membrane associated pattern recognition receptors stimulates the PI3K/Akt pathway resulting in decreased morbidity and increased survival outcome in fulminating sepsis. These data suggest that stimulation of the PI3K pathway may be an effective approach for preventing and/or treating sepsis/septic shock. In the current proposal, we will extend these studies to examine the cellular and molecular mechanisms by which glucan ligands stimulate PI3K/Akt signaling. We will focus on understanding the ligand-receptor interactions that activate PI3K, the postreceptor signal transduction events that stimulate PI3K/Akt/GSK3 and the cellular changes that culminate in modulation of PI3K and induction of the protective phenotype in sepsis injury. Not only will the results of this research increase our basic science knowledge of the innate response to inflammatory/septic disease, but it may also result in the development of new treatment strategies for several important disease states.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of an alpha-1 phosphate mannan vaccine against the emerging fungal pathogen Candida auris.
-
批准号:10573467
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2023
-
负责人:David L. Williams
-
依托单位:
Amelioration of Sepsis by Macrophage Activation
-
批准号:7939064
-
项目类别:
-
资助金额:$11.5万
-
财政年份:2009
-
负责人:David L. Williams
-
依托单位:
Dietary supplementation with glucan enhances immune fn
-
批准号:6534558
-
项目类别:
-
资助金额:$15.56万
-
财政年份:2001
-
负责人:David L. Williams
-
依托单位:
IMMUNE RECOGNITION OF CANDIDA--ROLE OF CELL WALL
-
批准号:6225237
-
项目类别:
-
资助金额:$24.16万
-
财政年份:2001
-
负责人:David L. Williams
-
依托单位:
Dietary supplementation with glucan enhances immune fn
-
批准号:6317216
-
项目类别:
-
资助金额:$15.47万
-
财政年份:2001
-
负责人:David L. Williams
-
依托单位:
BIOMOLECULAR INTERACTION ANALYSIS INSTRUMENTATION
-
批准号:2489127
-
项目类别:
-
资助金额:$22.9万
-
财政年份:1998
-
负责人:David L. Williams
-
依托单位:
Amelioration of Sepsis by Macrophage Activation
-
批准号:8235529
-
项目类别:
-
资助金额:$28.71万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
AMELIORATION OF SEPSIS BY MACROPHAGE ACTIVATION
-
批准号:6628698
-
项目类别:
-
资助金额:$25.39万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
Amelioration of Sepsis by Macrophage Activation
-
批准号:7281703
-
项目类别:
-
资助金额:$28.71万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
AMELIORATION OF SEPSIS BY MACROPHAGE ACTIVATION
-
批准号:2192894
-
项目类别:
-
资助金额:$15.38万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
AMELIORATION OF SEPSIS BY MACROPHAGE ACTIVATION
-
批准号:2685082
-
项目类别:
-
资助金额:$16.64万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
Amelioration of Sepsis by Macrophage Activation
-
批准号:7150183
-
项目类别:
-
资助金额:$29.57万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
AMELIORATION OF SEPSIS BY MACROPHAGE ACTIVATION
-
批准号:6498428
-
项目类别:
-
资助金额:$25.39万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
Amelioration of Sepsis by Macrophage Activation
-
批准号:7497484
-
项目类别:
-
资助金额:$28.71万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
AMELIORATION OF SEPSIS BY MACROPHAGE ACTIVATION
-
批准号:6262619
-
项目类别:
-
资助金额:$25.04万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
Amelioration of Sepsis by Macrophage Activation
-
批准号:8400886
-
项目类别:
-
资助金额:$27.7万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
AMELIORATION OF SEPSIS BY MACROPHAGE ACTIVATION
-
批准号:6698553
-
项目类别:
-
资助金额:$25.39万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
AMELIORATION OF SEPSIS BY MACROPHAGE ACTIVATION
-
批准号:2392260
-
项目类别:
-
资助金额:$16.0万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
AMELIORATION OF SEPSIS BY MACROPHAGE ACTIVATION
-
批准号:2900857
-
项目类别:
-
资助金额:$17.3万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
海外基金